Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Škrk Janez) .

1 - 10 / 20
Na začetekNa prejšnjo stran12Na naslednjo stranNa konec
1.
Cysteine proteinase inhibitors stefin A and stefin B in operable carcinoma of the head and neck : Inhibitorji cisteinskih proteinaz stefin A in stefin B pri operabilnem karcinomu glave in vratu
Primož Strojan, Marjan Budihna, Alojz Šmid, Branka Svetic, Ivan Vrhovec, Janko Kos, Janez Škrk, 2002, izvirni znanstveni članek

Povzetek: Purpose. To evaluate the significance of cysteine proteinase inhibitors stefins (Stefs) A and B for a treatment decision and prognosis in operable squamous cell carcinoma of the head and neck (SCCHN). Patients and methods. Stefs A and B concentrations were determined immunobiochemically using ELISAs in cytosols prepared from the tumor and adjacent normal mucosa from 91 patients with operable SCCHN. The median follow-up period of patients alive atthe close-out date was 5.8 years (range, 5-9.3 years). Results. Stef A concentrations were significantly higher in tumor compared to normal mucosa (FM.05). When a subgroup with clinically palpable nodes) at presentation was taken into consideration (n=57), a significant difference in Stef A (P=0.03) and Stef B (P=0.02) concentrations between those with negative and positive necks, as determined on histopathological examination, was observed. On the univariate survival analysis, higher Stefsć concentrations turned to be prognostically advantageous. Stef A proved its independent prognostic significance also on multivariate setting. Conclusions. With the capability todifferentiate between the pN0- and pN+-stages of the disease in the patientsoriginally presented as node-positive, Stefs A and B could be useful markers when deciding on the extent of neck surgery. In addition, both Stefs proved to be reliable prognosticators for survival in patients with operable SCCHN.
Objavljeno v DiRROS: 31.01.2024; Ogledov: 118; Prenosov: 29
.pdf Celotno besedilo (114,91 KB)

2.
Cathepsin D and plasminogen activator inhibitor type 1 in normal, benign and alignant ovarian tissues : a preliminary report
Marina Šprem, Damir Babić, Marija Abramić, Duško Miličić, Ivan Vrhovec, Janez Škrk, Maja Osmak, 2000, izvirni znanstveni članek

Povzetek: Background. The aim of the present study was to determine the concentration ofcathepsin D (Cath D) and plasminogen activator inhibitor type 1 (PAI-1) in normal ovarian tissues, benign and malignant ovarian tumor tissues, and to asses relationship between Cath D and PAI-1 content, and some clinical and pathohistological parameters. Materials and methods. Cath D contents and PAI-1concentrations were determined (using immunoradiometric ELSA-Cath D assayand commercial IMUDIND R ELISA immunoassay, respectively) in 35 samples: 10 normal ovarii, 10 benign, 10 primary malignant and 5 metastatic ovarian tumors. Results. The concentrations of Cath D were significantly higher in malignant (32.89+-14.26 pmol/mg protein ) and metastatic (31.42+-10.24 pmol/mgprotein), than in normal (13.68+-4.03 pmol/mg protein) and benign (17.89+-13.13 pmol/mg protein) ovarian tissues. There was no statistical differences in the concentrations of PAI-1 between normal, benign, malignant and metastatic tumor specimens. The concentrations of Cath D as well as PAI-1 did not correlate to the age of patients, menopausal status, parity, GOG risk group, clinical stage or pathohistological grading. Conclusion. Concentrationsof Cath D (but not PAI-1) were significantly increased in malignant and metastatic ovarian tumor tissues when compared to normal and benign ovarian tumor samples; they were independent from pathohistological andclinical parameters.
Objavljeno v DiRROS: 23.01.2024; Ogledov: 131; Prenosov: 51
.pdf Celotno besedilo (442,49 KB)

3.
Cathepsin H in squamous cell carcinoma of the head and neck
Primož Strojan, Marjan Budihna, Alojz Šmid, Branka Svetic, Ivan Vrhovec, Janko Kos, Janez Škrk, 1999, izvirni znanstveni članek

Objavljeno v DiRROS: 22.01.2024; Ogledov: 133; Prenosov: 36
.pdf Celotno besedilo (557,02 KB)

4.
Seventh international symposium on neutron capture therapy for cancer
Gregor Serša, Janez Škrk, 1996, drugi sestavni deli

Objavljeno v DiRROS: 16.01.2024; Ogledov: 154; Prenosov: 32
.pdf Celotno besedilo (108,08 KB)

5.
6.
7.
8.
Linearno-kvadratični model frakcioniranja u radioterapijskoj primjeni
M... Bistrović, Marjan Budihna, E... Čepulić, Marko Habič, Z... Kuzmanović, Janez Škrk, 1989, pregledni znanstveni članek

Objavljeno v DiRROS: 15.09.2023; Ogledov: 408; Prenosov: 59
.pdf Celotno besedilo (1,91 MB)

9.
10.
Iskanje izvedeno v 0.32 sek.
Na vrh